Research and analysis
Annex 3: Table 3
Updated 28 June 2021
Download CSV 1.04 KB
| Setting | Study Design | Comparator | Erythromycin, n*/N | Comparator, n*/N | Outcome | Study | Risk Estimate (95% Cl) | Rate per 1000 exposed to macrolide | Rate per 1000 exposed to comparator | Rate difference | Overall Bias |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Denmark 2000-2015 | Cohort | Penicillin | 182/5,037 | na /48,765 | MCM | Damkier et al 2019 | 1.09 (0.93-1.27) | n/a | n/a | n/a | serious |
| Quebec 1998-2009 | Cohort | Penicillin | 118/883 | 894/9,106 | MCM | Muanda et al 2017b | OR 1.25*(1.01-1.53) | 133.64 | 98.18 | 35.46 | serious |
| US Tennessee 1985-2000 | Cohort | unexposed | 23/559 | 102/3,400 | MCM | Cooper 2009 | RR 1.37 (0.85-2.22) | 41.14 | 30 | 11.14 | serious |
| Quebec 1998-2009 | Case-control | Penicillin | 110/n/a | 500/6,073 | Miscarriage | Muanda 2017a | aOR 1.91 (1.53–2.39) | n/a | n/a | n/a | moderate |
| Denmark 2000-2015 | Cohort | Penicillin | 57/5,037 | n/a | CVM | Damkier 2019 | aOR 1.14 (0.86-1.51) | n/a | n/a | n/a | serious |
| Quebec 1998-2009 | Cohort | Penicillin | 19/883 | 192/9,106(2.11) | CVM | Muanda 2017b | OR 0.92 (0.57-1.49) | 21.52 | 21.08 | 0.43 | serious |
| US Tennessee 1985-2000 | Cohort | unexposed | 7/559 | 37/3,400 | CVM | Cooper et al 2009 | RR 1.13 (0.5-2.55) | 12.52 | 10.88 | 1.64 | serious |